IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $263.50M, up 60.6% from the prior year. The company ran a net loss, with a net margin of -148.4%. It held $913.17M in total assets against $214.59M in total liabilities.
Key ratios (FY2025)
-153.1%
Operating margin
-148.4%
Net margin
-56.0%
Return on equity
+60.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.50M | $164.07M | $1.19M | — | — | — | — | — | — | — |
| Cost of Revenue | $173.18M | $93.25M | $1.03M | — | — | — | — | — | — | — |
| Operating Income | -$403.36M | -$395.28M | -$460.56M | -$398.88M | -$342.70M | -$261.94M | -$206.87M | -$128.26M | -$92.88M | -$53.64M |
| Net Income | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -$342.25M | -$259.58M | -$197.56M | -$123.58M | -$92.06M | -$52.89M |
| EPS (Diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | — | — | — |
| Total Assets | $913.17M | $910.43M | $780.35M | $663.98M | $777.33M | $768.46M | $344.65M | $480.82M | $155.37M | $171.89M |
| Total Liabilities | $214.59M | $200.02M | $195.74M | $164.34M | $155.67M | $111.96M | $45.68M | $14.63M | $9.89M | — |
| Shareholders' Equity | $698.58M | $710.40M | $584.61M | $499.64M | $621.66M | $656.50M | $298.97M | $466.19M | $145.48M | $166.92M |
| Cash & Equivalents | $163.08M | $115.69M | $114.89M | $231.73M | $78.23M | $67.33M | $13.97M | $82.15M | $145.37M | $106.72M |
| Operating Cash Flow | -$302.41M | -$352.98M | -$361.82M | -$292.76M | -$227.94M | -$205.13M | -$158.89M | -$101.25M | -$78.71M | -$32.67M |
| Capital Expenditures | $33.84M | $11.07M | $22.29M | $20.43M | $37.57M | $46.79M | $6.92M | $1.20M | $1.03M | $1.52M |
| Shares Outstanding | 411.94M | 305.25M | 256.14M | 187.81M | 157.00M | 147.87M | 126.41M | 123.42M | 73.16M | 62.25M |